马腾骧教授学术与教育思想(精)
①全新正版，现货速发，7天无理由退换货②天津仓、成都仓、无锡仓、广东仓、武汉仓等多仓就近发货，订单最迟48小时内发出③无法指定快递④可开电子发票，不清楚的请咨询客服。
￥ 223.89 6.8折 ￥ 328 全新
仅1件
浙江嘉兴
认证卖家担保交易快速发货售后保障
作者编者:牛远杰//韩瑞发//徐勇|责编:王培
出版社科技文献
ISBN9787518977970
出版时间2021-04
装帧精装
开本其他
定价328元
货号31190732
上书时间2024-10-04
- 在售商品 暂无
- 平均发货时间 15小时
- 好评率 暂无
商品详情
- 品相描述：全新
- 商品描述
-
作者简介
马腾骧教授1926年7月29日出生于辽宁省辽阳市。1948年毕业于盛京医科大学（后为辽宁医学院，学制6年，现并校为中国医科大学），同年到天津中央医院（现天津医科大学总医院）实习。1949年在天津中央医院做外科医师，1953年任泌尿外科主治医师。1957年，开展了国内首例回肠膀胱手术。1959年，在国内率先开展了人工肾应用于临床抢救急性肾衰并获得成功，标志着我国应用人工肾血液透析治疗急性肾衰进入临床应用新阶段。
20世纪60年代初期，马腾骧教授开展了天津市第一例同种异体肾移植手术；在国内首先开展了肾结核病保留肾单位手术和肾血管性高血压外科诊疗方法。主编出版了国内第一部《膀胱镜诊断学》和《人工肾》专著。1962年，任天津医学院外科学（泌尿外科）副教授。1971年，任天津医学院附属医院（现天津医科大学总医院）外科副主任。
1973年，马腾骧教授调入天津医学院附属医院分院（现天津医科大学第二医院）任外科副主任，是天津医科大学第二医院创始人之一，同年开始举办全国泌尿外科“医师进修班”。1975年，任天津医学院附属医院分院外科主任。1978年，晋升天津医学院外科学（泌尿外科）教授、主任医师。创建了天津医学院第二附属医院泌尿外科并任科主任。在天津市率先恢复并开展了肾脏移植工作，推动了泌尿外科在多领域的快速发展。
1979年，马腾骧教授紧跟时代步伐，高瞻远瞩，申请创建学科科研基地，经天津市政府批准，成立了天津市泌尿外科研究所，并由天津市市长聘任为首任所长。同年，马腾骧教授开始招收泌马腾骧教授（1926—2019年）尿外科专业硕士研究生，为学科发展培养了急需的专业人才。1980年，创建国内第一个大型现代化血液透析中心，推动了我国血液透析事业的快速发展，在国际同专业领域达到先进水平。
1980年，马腾骧教授任天津医学院第二附属医院副院长，1983年，任天津医学院第二附属医院院长。1982年，受卫生部委托先后举办了全国泌尿外科医师“部办班”24期。1984年，泌尿外科学科被确认为天津医学院首批重点学科，马腾骧为学科带头人。1985年，马腾骧教授被国务院批准为博士生导师。
1989年以来，马腾骧教授先后担任第3届至第5届中华医学会泌尿外科学分会副主任委员，《中华泌尿外科杂志》第3届至第5届副主编，天津市医学会泌尿外科学分会主任委员，中国生物医学工程学会生物材料分会副主任委员、人工器官分会主任委员。1990年，担任《透析与人工器官》杂志主编。
1994年，马腾骧教授获全国第一届吴阶平-保罗·杨森医学药学奖一等奖。天津医学院泌尿外科学科被评审为天津市首批重点学科，马腾骧为学科带头人。1996年，泌尿外科学科经教育部评审，正式立项列入国家“211工程”天津医科大学重点建设学科，马腾骧为学科带头人。1999年，泌尿外科成立临床医学博士后流动站点。2000年，“膀胱移行上皮癌诊断治疗及应用基础研究”获国家科学技术进步奖二等奖；2001年，马腾骧被聘为天津医科大学第二医院终身教授。
2002年，天津医科大学泌尿外科学科被教育部评审为国家重点学科，2004年被评为天津市“重中之重”建设学科，马腾骧任学科带头人。同年，天津市泌尿外科研究所被评审为天津市泌尿外科基础医学重点实验室，马腾骧首任重点实验室主任和天津市重点实验室学术委员会主任委员。2004年，天津市泌尿外科研究所成为生物医学工程博士后学位授权点和生物医学工程博士后工作站。2005年，马腾骧任天津市泌尿外科研究所名誉所长。2008年，马腾骧被中华医学会泌尿外科学分会授予“突出贡献奖”。
马腾骧教授是我国著名的泌尿外科专家和临床医学科学家，在他从医执教60余年的生涯中，他热爱医学事业，把毕生的精力奉献给了泌尿外科事业。始终以解除患者的痛苦、满足患者的需求和保障人民身体健康为己任。在临床医疗实践与科学研究中以严谨的科学态度，锲而不舍、孜孜以求和务实创新的探索精神，解决了许多临床重大疾病疑难问题。20世纪50年代，他在国内率先开展了腹膜透析和人工肾治疗急性肾衰患者，挽救了来自全国各地急性肾衰患者的生命。建立了肾血管性高血压新的诊疗方法，开创了局灶性肾结核保留肾单位手术，冲破了传统肾结核手术禁忌的束缚，建立了早期肾结核外科治疗的新方法，填补了国内空白并推广应用。20世纪60马腾骧教授生平简介年代，马腾骧教授在国内首先开展了“回肠膀胱术”，创建了“改良式乳头法输尿管肠吻合术”，迄今仍是根治性膀胱癌尿流改道的首选方法。为我国泌尿外科在相关领域的快速发展做出了重大贡献。
20世纪80年代，需要血液透析的慢性肾衰患者日益增多，原有的透析室已不能满足患者的需求，马腾骧教授对患者感同身受，在条件艰苦且极为困难的情况下，以高尚的医德情操和不畏艰难、砥砺奋斗的探索实践精神，建立了国内第一个大型现代
目录
第一篇 马腾骧教授人生历程与实践探索60年足迹
马腾骧教授的人生历程与从医之路 ·········································································3
实践·探索60年的足迹——对几件有意义往事的回忆 ··············································32
关于科室建设、学科发展的思路与足迹 ··································································39
创建科研基地 建设一流学科 ··············································································49
感悟马老人才培养与学科建设理念 ········································································64
院校领导的支持是学科可持续发展的动力 ·······························································75
传承发展——写好现代泌尿外科学 ········································································81
第二篇 实践孕育着探索 探索必须依赖实践
内容提要 ·········································································································87
急性功能衰竭的诊断问题 ·················································································90
人工肾临床使用的适应证 ····················································································94
急性肾机能不全的人工肾治疗 ··············································································99
外科性急性肾机能不全的透析治疗 ······································································106
血管内皮细胞素与急性肾功能衰竭 ······································································113
移植肾的急性肾功能衰竭 ··················································································117
血液透析中心的质量管理 ··················································································123
甘露醇对外科性急性肾功能不全的预防作用 ··························································131
胸腺肽对维持性血液透析患者T淋巴细胞功能的影响 ·············································136
维持性血液透析患者T淋巴细胞对外源性IL-2的增殖反应 ······································140
血液透析患者血清中分子物质与末梢神经障碍的实验研究 ········································144
慢性血液透析病人的多形核白细胞功能改变和透析的影响 ········································150
血液透析患者微量元素锌与免疫功能的相关性研究 ·················································158
维持性血液透析患者T淋巴细胞功能低下机理的探讨 ·············································162
血液透析患者应用含锌透析液的探讨 ···································································165
经透析液补锌对维持性血液透析患者免疫功能的影响 ··············································167
经透析液补锌对维持性血液透析患者T细胞功能影响的观察 ····································170
用改良大部分肾切除法制作的慢性肾衰动物模型 ····················································174
肾脏移植二年回顾与展望 ··················································································178
开展慢性血液透析的体会 ··················································································182
铜仿膜透析器对T淋巴细胞功能的影响 ·······························································186
尿毒症患者外周血T淋巴细胞亚群的测定（摘要） ················································190
慢性肾衰大鼠细胞免疫功能的初步研究 ································································192
Reduced Glutathione（GSH）and Erythrocyte Deformability of Hemodialysis Patients ·········197
第三篇 务实创新——探索异种移植肾的相关基础研究
内容提要 ·······································································································205
异种器官移植用血管内皮细胞特异表达人DAF重组基因载体的构建 ··························207
异种器官移植用血管内皮细胞特异表达人CD59重组基因的构建 ·······························215
异种移植转基因用含粘附分子-2启动子的人CD59重组基因的构建 ··························222
逆转录病毒载体介导白细胞介素-10基因转染对移植物保护作用 ······························230
异种移植血管内皮细胞组织特异性表达人CD59转基因小鼠的建立 ····························234
32磷标记供体白细胞静脉注射预处理对兔同种皮肤移植存活的延长作用 ······················239
建立血管内皮细胞组织特异性表达人衰变加速因子的转基因小鼠 ·······························246
人DAF基因在转基因小鼠中的遗传与表达 ···························································253
携带人衰变加速因子基因转基因小鼠的建立 ··························································261
使用人粘附分子-2启动子的衰变加速因子重组基因表达载体的构建及意义 ·················267
大鼠白细胞介素10（IL-10）CDNA的克隆及在大肠杆菌中的表达 ····························272
血管内皮细胞组织特异性表达人CD59基因转基因小鼠传代及表达检测 ······················277
异种移植模型转人α1，2岩藻糖基转移酶基因小鼠显微注射DNA片段的制备 ·············283
Ki-67基因 SIRNA表达质粒的构建、鉴定及功能研究 ·············································290
人α1，2岩藻糖苷转移酶基因在猪动脉内皮细胞的表达 ··········································296
异种移植转基因用含杂合增强子UI的人衰变加速因子重组基因的构建 ·······················302
第四篇 从矛盾的普遍性探索肾疾病诊疗方法的特殊性
内容提要 ·······································································································311
肾结核部分肾切除术 ························································································312
病灶切开术治疗肾结核症之观察 ·········································································319
肾切除治疗泌尿系统结核症的观察 ······································································329
部分肾切除治疗肾结核症的进一步观察 ································································335
加强交流，提高肾上腺外科医疗水平；重视科研，促进我国肾上腺外科迅速发展 ··········340
131碘-碘锐特（131Ⅰ-Diodrast）肾放射图的临床应用 ·············································342
肾血管性高血压诊断及治疗的进一步观察 ·····························································354
腹主动脉-肾动脉造影在肾源性高血压病诊断上的应用 ··········································364
实验性肾血管性高血压：抑制试验与激发试验下肾素分泌与肾素系统功能测定 ·············372
肾动脉栓塞术治疗肾癌的意义 ············································································379
人参皂甙对肾脏代偿性生长的影响 ······································································383
125I偶联反义核酸对裸鼠肾癌移植瘤的治疗作用 ·····················································388
Knockdown of Ki-67 by Small Interfering RNA Leads to Inhibition of Proliferation and Induction of Apoptosis in Human Renal Carcinoma Cells ···········································394
Treatment with Vector-expressed Small Hairpin RNAs Against Ki67 RNA-induced Cell Growth Inhibition and Apoptosis in Human Renal Carcinoma Cells ·······························407
第五篇 从肠管在尿流改道中的应用到膀胱癌防治研究与实践
内容提要 ·······································································································423
自体小肠肠管在泌尿外科中的应用 ······································································425
输尿管、末段回肠、皮肤造瘘术 ·········································································434
肠、膀胱成形术治疗结核性膀胱挛缩的察 ··························································440
Uretero-Ileo-Cutaneostomy ·················································································447
加强卡介苗膀胱灌注对治疗和预防膀胱上皮癌术后复发的机理研究 ····························454
加强膀胱癌的综合研究 提高膀胱癌临床防治水平 ·················································456
卡介苗抗肿瘤作用机制的实验与临床研究进展 ·······················································458
膀胱内灌注卡介苗抗肿瘤作用机制的探讨 ·····························································465
BCG灌注对膀胱癌与黏膜上皮组织HLA·DR抗原表达的定位研究 ···························474
BCG灌注对外周血免疫细胞的调节及其功能的影响 ················································478
BCG对膀胱黏膜结构的影响及肿瘤超微病理的研究 ················································484
phIFN-α-2B穿梭质粒在卡介苗中的表达 ······························································488
TGF-β1对膀胱移行细胞癌细胞黏附性的调节 ·························································494
TGF-β1对BCG抗膀胱癌作用的研究 ···································································500
纤维粘连蛋白的导入对BCG与膀胱癌细胞黏附的影响 ············································506
在分子生物学水平上对膀胱癌的发生与治疗进行深入的研究 ·····································512
多胺测定与膀胱癌 ···························································································514
多药耐药基因与膀胱癌 ·····················································································518
膀胱肿瘤抗药机制的实验研究 ············································································523
纤维粘连蛋白对膀胱癌细胞生物学行为的影响 ·······················································529
钙通道阻断剂逆转膀胱癌细胞耐药性的实验研究 ····················································535
超氧化物歧化酶与膀胱癌分级分期关系的研究 ·······················································541
TGF-β1蛋白的表达对膀胱癌生物学行为的影响 ······················································547
人体膀胱移行细胞癌细胞系TBC-27的建立及其生物学特性 ·····································552
抑癌基因P
— 没有更多了 —
以下为对购买帮助不大的评价